EVerZom
Latest round
- Series A
Last raised
- Oct 2025
Total raised
- $12M
Investors
- 5
About EVerZom
EVerZom is a biotechnology company focused on developing exosome-based therapeutics for regenerative medicine, specifically targeting healing processes in digestive and organ tissues. Founded in 2019 and headquartered in Paris, France, EVerZom specializes in exosome technology for regenerative therapies. The founders include Amanda Brun, Jeanne Volatron, and Max Piffoux, with Jeanne Volatron currently serving as CEO. EVerZom develops innovative exosome-based therapeutics for regenerative medicine, featuring two primary drug candidates. One focuses on healing digestive tissues aimed at Crohn’s fistula, while the other is designed for organ regeneration, specifically for the liver and kidney. The company utilizes its proprietary platform that encompasses exosome generation and formulation, supported by multiple patents.EVerZom generates revenue through partnerships and collaborations with pharmaceutical companies, advancing its therapeutic programs via co-development agreements and potential licensing of its technologies in regenerative medicine. The company’s primary products are in preclinical stages, addressing significant healthcare challenges in digestive and organ injuries.
Who invested in EVerZom
5 investors across 1 round
See all investors in EVerZom
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 3, 2025
Amount
$12M
Investors
Questions about EVerZom
Who invested in EVerZom?
EVerZom has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has EVerZom raised?
EVerZom has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did EVerZom last raise money?
EVerZom's most recent round on record is a Series A, in Oct 2025.
What does EVerZom do?
EVerZom is a biotechnology company focused on developing exosome-based therapeutics for regenerative medicine, specifically targeting healing processes in digestive and organ tissues.
Where is EVerZom headquartered?
EVerZom is headquartered in Paris, France.
Which VCs invest in companies like EVerZom?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at EVerZom's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like EVerZom? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.